Theory Paper IIIDrNB Cardiology – Theory Notes

CAROTID BARORECEPTOR STIMULATION (BAROREFLEX ACTIVATION THERAPY - BAT)

2-page exam answerLast reviewed: October 2026
Merit MedScript seal

IINTRODUCTION AND DEFINITION

  • Definition: Baroreflex Activation Therapy (BAT) is a surgical device-based neuromodulation therapy (Barostim Neo system) that delivers continuous, programmable electrical stimulation to the mechanoreceptors of the carotid sinus.
  • Therapeutic Objective: Directly restores autonomic sympathovagal balance by suppressing maladaptive central sympathetic overdrive and augmenting vagal (parasympathetic) activity—targeting the shared neurohormonal driver of Heart Failure with Reduced Ejection Fraction (HFrEF) and Resistant Hypertension.

IIPATHOPHYSIOLOGY AND NEURAL MECHANISM OF ACTION

  • Afferent Neural Pathway: A miniature 2-mm extravascular electrode is sutured onto the adventitia of the carotid sinus (typically unilaterally on the right side). Electrical impulses activate carotid sinus baroreceptor afferents, which transmit action potentials along the Carotid Sinus Nerve of Hering (a branch of the Glossopharyngeal Nerve, CN IX) to the Nucleus Tractus Solitarius (NTS) in the medulla oblongata.
  • Central Medullary Integration: The NTS interprets this sustained afferent input as elevated arterial stretch/pressure, activating caudal ventrolateral medullary inhibitory interneurons that suppress the Rostral Ventrolateral Medulla (RVLM — the sympathetic vasomotor center) while stimulating the Nucleus Ambiguus and Dorsal Motor Nucleus of the Vagus.
  • Efferent Physiological Triad (Heart, Vasculature, Kidneys):
    • Cardiac Effects: Restored parasympathetic vagal tone and reduced beta-1 sympathetic drive lower resting heart rate, reduce myocardial oxygen consumption, reverse beta-receptor downregulation, and increase the ventricular fibrillation threshold.
    • Vascular Effects: Sympathetic withdrawal induces arterial vasodilation (lowering Systemic Vascular Resistance [SVR] and LV afterload) and splanchnic venodilation (increasing venous capacitance and lowering cardiac filling pressures).
    • Renal Effects: Inhibits renal efferent sympathetic nerve activity to the juxtaglomerular apparatus and proximal tubules, suppressing renin-angiotensin-aldosterone system (RAAS) activation and promoting pressure-independent natriuresis.

IIILANDMARK CLINICAL TRIALS AND CURRENT STATUS

AHeart Failure with Reduced Ejection Fraction (HFrEF) — The BeAT-HF Trial

  • Trial Design and Target Population: Randomized 408 patients (264 in the expedited phase; 323 in the extended long-term phase) with symptomatic HFrEF (LVEF <=35%), NYHA Functional Class III (or Class II with recent HF hospitalization), NT-proBNP <1,600 pg/mL, and ineligibility for Cardiac Resynchronization Therapy (CRT; QRS <130 ms) to BAT + Optimal GDMT versus GDMT Alone.
  • Primary Outcomes:
    • 6-Month Functional and Biomarker Endpoints (JACC 2020): Demonstrated highly significant improvements in 6-Minute Walk Distance (+60 meters; p < 0.001), Quality of Life (MLWHFQ score -14.1 points; p < 0.001), and a 25 percent reduction in NT-proBNP (p = 0.004), with 97 percent freedom from MANCE complications.
    • Long-Term Post-Market Phase (Eur J Heart Fail 2024): While the primary composite of CV death and HF morbidity was neutral (RR 0.94; p = 0.82), BAT maintained durable 24-month functional/QoL gains; post hoc analyses suggested fewer deaths, LVAD implants or transplants (hypothesis-generating only).
    • FDA Regulatory Status: FDA-approved for improving symptoms and functional status in patients with LVEF <=35%, NYHA Class III (or II), NT-proBNP <1,600 pg/mL, and no Class I indication for CRT.

BResistant Hypertension — The Rheos Pivotal Trial and Barostim Neo Registries

  • First-Generation Rheos Pivotal Trial (JACC 2011): Double-blind randomized trial (n = 265) of the first-generation bilateral device; met long-term 12-month efficacy (53% achieved SBP <=140 mmHg with a ~26 to 35 mmHg SBP drop), but failed its co-primary 6-month acute responder endpoint and 30-day procedural nerve-safety endpoint (due to cranial nerve injuries from bilateral circumferential carotid dissection).
  • Second-Generation Unilateral Barostim Neo: Eliminates posterior carotid dissection and achieves a >95% complication-free safety profile with sustained 25 to 30 mmHg office SBP reductions in European registries; however, due to the requirement for surgical generator implantation and lack of a new sham-controlled RCT, it remains an investigational / last-resort therapy behind Renal Denervation (RDN) in the 2024 ESC / 2023 ESH Hypertension Guidelines.
Parameter BAT in HFrEF (BeAT-HF Phenotype) BAT in Resistant Hypertension
Eligibility Criteria LVEF <=35%, NYHA Class III, NT-proBNP <1,600 pg/mL, and NO CRT indication (QRS <130 ms) despite optimal Quadruple GDMT True drug-refractory hypertension (>=4–5 drugs including Spironolactone) failing or unsuitable for Renal Denervation
Primary Proven Benefit +60 m 6MWD, -14.1 pt MLWHFQ QoL, -25% NT-proBNP (BeAT-HF, JACC 2020) -25 to -30 mmHg office SBP & -8 to -13 mmHg 24-h ABPM in Barostim Neo registries
Guideline & FDA Status FDA Approved for symptoms/QoL; no formal class in 2021 ESC / 2022 AHA-ACC HF Guidelines Not FDA approved for HTN (humanitarian exemption only for prior Rheos responders); Investigational in ESC 2024

IVCLINICAL GUIDELINES, PATIENT SELECTION AND CONTRAINDICATIONS

  • Strict HFrEF Selection Checklist (The Four Criteria):
    • Left Ventricular Ejection Fraction <= 35 percent on maximally tolerated Quadruple GDMT.
    • Persistent NYHA Class III symptoms (or Class II with recent Class III decompensation).
    • Ineligible for Cardiac Resynchronization Therapy (CRT)—specifically QRS duration < 130 ms (or non-LBBB <150 ms).
    • Baseline NT-proBNP < 1,600 pg/mL (identifying patients before irreversible end-stage pump failure).
    • Contraindications:
    • Carotid Artery Stenosis (>50%) or Ulcerative/Calcific Plaque at the Carotid Bifurcation (risk of perioperative embolic stroke during lead suturing).
    • Prior Neck Surgery, Tracheostomy, or Cervical Radiation obliterating the carotid anatomical plane.
    • Bilateral Carotid Body Paragangliomas, Baroreflex Failure, or Severe Autonomic Neuropathy.
    • Symptomatic Bradyarrhythmias (Sick Sinus Syndrome or High-Grade AV Block) unless protected by a permanent pacemaker.

Key references

  • Zile MR, Lindenfeld J, Weaver FA, et al. (BeAT-HF Investigators): Baroreflex Activation Therapy in Patients With Heart Failure With Reduced Ejection Fraction, Journal of the American College of Cardiology, 2020.
  • Zile MR, Lindenfeld J, Weaver FA, et al. (BeAT-HF Investigators): Baroreflex activation therapy in patients with heart failure: the randomized BeAT-HF trial long-term outcomes, European Journal of Heart Failure, 2024.
  • Bisognano JD, Bakris G, Nadim MK, et al. (Rheos Pivotal Trial Investigators): Baroreflex activation therapy lowers blood pressure in patients with resistant hypertension, Journal of the American College of Cardiology, 2011.
  • Heidenreich PA, Bozkurt B, Aguilar D, et al.: 2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure, Circulation, 2022.
meritmedscript.comDr. Sidhartha Mullapudi

Was this answer useful?

Your rating helps decide which topics to expand next.

Report an error

Spotted something outdated or incorrect? Tell us and we will check it against the source.